NICE does not recommend imatinib at a dose of 600 or 800 mg a day for people with unresectable and/or metastatic GISTs whose disease has got worse after treatment with imatinib at a dose of 400 mg a day.

This guidance updates Imatinib for the treatment of unresectable and/or metastatic gastrointestinal stromal tumours (NICE technology appraisal guidance 86).

Recommendation 1.5 in TA86 has been replaced. All the other recommendations in TA86 still apply. Please see the guidance for more information.

Why has NICE said this?

NICE looks at how well treatments work, and also at how well they work in relation to how much they cost the NHS. NICE applies special considerations to treatments that can extend the lives of people who are nearing the end of their life. There is not enough evidence from clinical trials to say how well an increased dose of imatinib works, or whether it works well enough to justify its cost, so NICE did not recommend it.

  • National Institute for Health and Care Excellence (NICE) accreditation logo